PROJECT SUMMARY
Postoperative pneumonia occurs in ~2-8% of patients following various surgeries and increases the length of
hospital stay and mortality. Pneumonia is a common cause of sepsis. Some pneumonia survivors, including
those with post-intensive care unit syndrome, suffer from cognitive deficits, reducing their quality of life and
inflicting healthcare and financial hardships. Strikingly, pneumonia-associated microorganisms (e.g., P.
aeruginosa) trigger lung endothelial production and release of several cytotoxic amyloids (e.g., tau and Aβ) that
are key pathological hallmarks of dementia. Cytotoxic tau produced by lung endothelial cells in response to
bacterial pneumonia infection accumulates in the brain, reduces dendritic spine density, impairs learning and
memory, and causes neuronal tauopathy. We recently found that P. aeruginosa infection causes blood-brain
barrier breakdown and gliosis. There is growing appreciation and strong evidence that neurovascular uncoupling,
cerebral blood flow reductions and dysregulation, and breakdown of the blood-brain barrier, including the loss of
pericytes, are early events leading to cognitive decline and dementia, including in the setting of pneumonia and
infections. Apolipoprotein (APOE)-ε4 is the greatest genetic risk factor for sporadic dementia, increases infection
severity (e.g., SARS-CoV-2) and promotes blood-brain barrier damage and pericyte degeneration. Whether
pneumonia-elicited lung endothelial cytotoxic tau variants initiate blood-brain barrier breakdown to induce
neurovascular unit dysfunction (e.g., pericyte injury, gliosis, and impaired hemodynamics), and whether APOE-
ε4-induced neurovascular unit dysfunction exacerbates the negative impact of lung endothelial tau on the brain
remains to be determined and are the focus of this study. Using state-of-the-art methodologies, this proposal
innovatively uses 1) fast-speed, high-resolution two-photon intravital microscopy, 2) quantitative tau and
neurovascular unit plasma assays, 3) pathological assessment of lung tau and neurovascular unit dysfunction
in post-mortem human tissue, 4) lung endothelium targeted mice and adeno-associated viruses, and 5) anti-tau
antibodies. This proposal tests the scientifically supported and novel hypotheses that 1) lung endothelial tau
disrupts the neurovascular unit, 2) APOE-ε4 exacerbates the impact of lung endothelial tau on the neurovascular
unit, and 3) anti-tau antibodies to prevent neurovascular unit dysfunction caused by pneumonia. This is a
translational preclinical project bridging in vitro experiments, experimental models and clinical samples, and is
pioneering in that it synthesizes experts in lung and brain biology to understand the impact of pneumonia-elicited
lung endothelial tau on neurovascular unit functions, with consideration of health disparities.